MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 ...
Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ ...
Outpatient early methadone dose titration – as recommended in Canadian and US clinical guidance for individuals using fentanyl – is associated with improved treatment retention and lower risk of ...
Chronic illness has a way of sharpening your perspective. It exposes where systems rely heavily on patient endurance and how quickly women’s symptoms can be minimized.
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to Initiate in April 2026 On March 18 ...
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal ...
To investigate the effects of glycine betaine (GB) on the quality and yield of little cherry, a foliar spray experiment was ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes improved time in range after ...
Vanda Pharma begins Thetis study, a clinical trial of Nereus for prevention of vomiting induced by GLP-1 receptor agonists: Washington Friday, April 10, 2026, 14:00 Hrs [IST] Vand ...
Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat ...
Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results